NewsEvents

Your Yourlocation: Home > Efficacy of tiotropium bromide(136310-93-5) in the treatment of moderate to severe chronic obstructive pulmonary disease

To evaluate the clinical efficacy and safety of inhaled tiotropium bromide(136310-93-5) in the treatment of moderate to severe chronic obstructive pulmonary disease(COPD).

Methods: Sixty - five patients with moderate to severe COPD were randomly divided into treatment group(n = 31) and control group(n = 34). The control group was given conventional treatment. The treatment group was given inhaled tiotropium bromide powder (18μg, once /d) for 12 weeks on the basis of conventional treatment. The changes of dyspnea score, the change of lung function and the number of acute exhalation in 12 weeks were observed before and after treatment for 4 weeks and 12 weeks.

Results: There was significant difference between the two groups in the treatment group (P <0.01), FEV1 and FEV1 /FVC were significantly higher than those before treatment (P <0.01), and there was no significant difference between the two groups difference. There was no significant difference between the two groups(P> 0.05). Common adverse effects of tiotropium are dry mouth, no cardiovascular system abnormalities and abnormal ECG reports.

Conclusion: Tiotropium bromide(136310-93-5) is a safe and effective bronchodilator for the treatment of moderate to severe COPD, which can significantly improve the clinical symptoms and pulmonary function of patients, and is safe and reliable.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved